Recurrent Ameloblastoma: Clinical Manifestation and Disease-Free Survival Rate.
Andrii HreskoRoman PalyvodaOlha BurtynYurii ChepurnyiAndrii KopchakMarco N HelderTymour ForouzanfarPublished in: Journal of oncology (2022)
Results obtained in the present retrospective study proved the necessity of long-term follow-up after both conservative and radical treatment approaches. The DFS median in our study was 8 years (95% CI 6 years-10 years). For recurrent cases, radical resection with histologically free margins after exact MRI determination of the ameloblastoma border within the soft tissues should be considered as the method of choice to avoid secondary recurrence.